ABIO Key Stats
- ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers Yahoo 03/03 17:22 ET
- 4 Biotech Stocks Under $10 Moving Higher Yahoo 02/26 06:00 ET
- ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Shareholder Director Nominations Yahoo 02/18 16:31 ET
- ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits Yahoo 02/12 17:30 ET
- Dan Mitchell Joins ARCA biopharma Board of Directors Business Wire 02/12 09:15 ET
- ARCA BIOPHARMA, INC. Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders Yahoo 02/10 16:29 ET
- ARCA Biopharma prices $9M common stock and warrant offering Yahoo 02/04 08:50 ET
- ARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit Yahoo 02/04 08:38 ET
- ARCA biopharma (ABIO) Prices Common Stock Offering at $1.70, with Warrants to Boot Street Insider 02/04 08:36 ET
- ARCA biopharma (ABIO) Prices $8.7M Stock, Warrants Offering Street Insider 02/04 08:36 ET
ABIO Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). ARCA biopharma is down 14.61% over the last year vs S&P 500 Total Return up 24.45%, Onconova Therapeutics up N/A, and NuPathe up 23.19%.
Balance Sheet View Statement
Pro Ratings for ABIO
Pro Strategies Featuring ABIO
Did ARCA biopharma make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: Colorado
- Incorporation Country: United States
- Incorporation State/Province: Delaware
ARCA biopharma, Inc. is a Colorado-based biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. ARCA’s principal focus is to develop personalized therapies for the treatment of cardiovascular disease through the use of genetics. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics and clinical development.